{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:50:33Z","timestamp":1758477033771},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00280-020-04057-5","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T10:03:44Z","timestamp":1585821824000},"page":"869-880","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model"],"prefix":"10.1007","volume":"85","author":[{"given":"Shuhei","family":"Sakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kobuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sakaeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"4057_CR1","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/jnci\/djp328","volume":"101","author":"MW Saif","year":"2009","unstructured":"Saif MW, Choma A, Salamone SJ, Chu E (2009) Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543\u20131552","journal-title":"J Natl Cancer Inst"},{"key":"4057_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78:447\u2013464","journal-title":"Cancer Chemother Pharmacol"},{"key":"4057_CR3","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012","journal-title":"J Clin Oncol"},{"key":"4057_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","volume":"34","author":"Y Guo","year":"2016","unstructured":"Guo Y, Xlong BH, Zhang T, Cheng Y, Ma L (2016) XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest 34:94\u2013104","journal-title":"Cancer Invest"},{"key":"4057_CR5","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097\u20134106","journal-title":"J Clin Oncol"},{"key":"4057_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishisa M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorourcil selectivity in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274\u20131281","journal-title":"Eur J Cancer"},{"key":"4057_CR7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S0968-0896(00)00087-0","volume":"8","author":"N Shimma","year":"2000","unstructured":"Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, Ishitsuka H (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem 8:1697\u20131706","journal-title":"Bioorg Med Chem"},{"key":"4057_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/A:1023525513696","volume":"21","author":"KS Blesch","year":"2003","unstructured":"Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL (2003) Clinical pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 21:195\u2013223","journal-title":"Invest New Drugs"},{"key":"4057_CR9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S0959-8049(98)00226-3","volume":"34","author":"NJ Meropol","year":"1998","unstructured":"Meropol NJ (1998) Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 34:1509\u20131513","journal-title":"Eur J Cancer"},{"key":"4057_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00280-016-3067-x","volume":"78","author":"KN Pilanci","year":"2016","unstructured":"Pilanci KN, Saglam S, Okyar A, Yucel S, Pala-Kara Z, Ordu C, Namal E, Ciftci R, Iner-Koksal U, Kaytan-Saglam E (2016) Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: a Phase II Brunch regimen study. Cancer Chemother Pharmacol 78:143\u2013150","journal-title":"Cancer Chemother Pharmacol"},{"key":"4057_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2131\/jts.31.265","volume":"31","author":"H Shindoh","year":"2006","unstructured":"Shindoh H, Kawashima A, Shishido N, Nakano K, Kobayashi K, Horii I (2006) Relationship between AUC of 5\u2032-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5\u2032-DFUR in monkeys, mice, and rats. J Toxicol Sci 31:265\u2013285","journal-title":"J Toxicol Sci"},{"key":"4057_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejps.2017.11.021","volume":"112","author":"S Kobuchi","year":"2018","unstructured":"Kobuchi S, Yazaki Y, Ito Y, Sakaeda T (2018) Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rat. Eur J Phaarm Sci 112:152\u2013158","journal-title":"Eur J Phaarm Sci"},{"key":"4057_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2131\/jts.36.411","volume":"36","author":"H Shindoh","year":"2011","unstructured":"Shindoh H, Nakano K, Yoshida T, Ishida M (2011) Comparison of in vitro conversion of capecitabine to 5-FU in rats, mice, monkeys and humans: toxicological implications. J Toxicol Sci 36:411\u2013422","journal-title":"J Toxicol Sci"},{"key":"4057_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1021\/bp990057t","volume":"15","author":"DJ Quick","year":"1999","unstructured":"Quick DJ, Shuler ML (1999) Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol Prog 15:540\u2013555","journal-title":"Biotechnol Prog"},{"key":"4057_CR15","first-page":"353","volume":"70","author":"K Ikenaka","year":"1979","unstructured":"Ikenaka K, Shirasaka T, Kitano S, Fujii S (1979) Effect of uracil on metabolism of 5-fluorouracil in vitro. GANN 70:353\u2013359","journal-title":"GANN"},{"key":"4057_CR16","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1023\/A:1010939329562","volume":"18","author":"Y Tsukamoto","year":"2001","unstructured":"Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y (2001) A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug og 5-FU, in humans: the mechanism for tumor-selective assumulation of 5-FU. Pharm Res 18:1190\u20131202","journal-title":"Pharm Res"},{"key":"4057_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1023\/A:1006263400888","volume":"17","author":"IR Judson","year":"1999","unstructured":"Judson IR, Beale PJ, Trigo JM, Aherene W, Cromptom T, Jones D, Bush E, Reigner B (1999) A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 17:49\u201356","journal-title":"Invest New Drugs"},{"key":"4057_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093\u20131095","journal-title":"Pharm Res"},{"key":"4057_CR19","first-page":"462","volume":"283","author":"T Iwatsubo","year":"1997","unstructured":"Iwatsubo T, Suzuki H, Sugiyama Y (1997) Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J Pharmacol Exp Ther 283:462\u2013469","journal-title":"J Pharmacol Exp Ther"},{"key":"4057_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jjco\/hyl058","volume":"36","author":"I Hyodo","year":"2006","unstructured":"Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K, Tamura T, Takemiya S, Takiuchi H, Nakagawa K, Mishima H (2006) A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 36:410\u2013417","journal-title":"Jpn J Clin Oncol"},{"key":"4057_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1124\/dmd.118.081737","volume":"46","author":"E Hishinuma","year":"2018","unstructured":"Hishinuma E, Narita Y, Saito S, Maekawa M, Akai F, Nakanishi Y, Yasuda J, Nagasaki M, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M (2018) Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1,070 Japanese individuals. Drug Metab Dispos 46:1083\u20131090","journal-title":"Drug Metab Dispos"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04057-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-020-04057-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04057-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T23:29:07Z","timestamp":1617319747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-020-04057-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4057"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04057-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"25 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the experiments were approved by the institutional review board and performed in accordance with the Kyoto Pharmaceutical University Guidelines for Animal Experimentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}